About: Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $23.34 (-16.43%)
TNGX NASDAQ Tango Therapeutics Inc
Tango Therapeutics Inc share price
Atividade de preço de TNGX
Último preço
$ 23,340
Variação (24h)
-4,59 USD (16,43%)
Volume
15.85M
Volume (média 4 sem.)
-
Abertura
$ 25,54
Variação do dia
$ 22,68 - $ 25,94
Fechamento anterior
$ 27,93
Último negócio
23 Oct, 8:28 pm GMT+0
Atrasado
23 Oct, 8:28 pm GMT+0
TNGX price performance
Atrasado
23 Oct, 8:28 pm GMT+0
quote.marketSignals